
## CLAIMS

[Claim 1] A salt of a compound I, wherein the salt is selected from a fumarate salt and a p-toluenesulfonate salt



I .

[Claim 2] The salt of the compound I of claim 1, being a crystal form A of the fumarate salt of the compound I, characterized in that an XRPD pattern of the crystal form A comprises diffraction peaks at 2θ of 5.44±0.2°, 9.75±0.2°, and 18.43±0.2°.

[Claim 3] The salt of the compound I of claim 2, being a crystal form A of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form A further comprises diffraction peaks at 2θ of 17.28±0.2°, 18.13±0.2°, 26.55±0.2°, and 27.86±0.2°.

[Claim 4] The salt of the compound I of claim 2 or 3, being a crystal form A of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form A further comprises diffraction peaks at 2θ of 10.99±0.2°, 12.09±0.2°, 13.89±0.2°, 14.87±0.2°, 16.25±0.2° and 19.11±0.2°.

[Claim 5] The salt of the compound I of any one of claims 2 to 4, being a crystal form A of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form A further comprises diffraction peaks at 2θ of 15.63±0.2°, 20.48±0.2°, 21.55±0.2°, 22.14±0.2°, 22.55±0.2°, 23.56±0.2°, 23.83±0.2°, and 29.86±0.2°.

[Claim 6] The salt of the compound I of any one of claims 2 to 5, being a crystal form A of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form A further comprises diffraction peaks at 2θ of 12.84±0.2°, 16.56±0.2°, 16.74±0.2°, 17.02±0.2°, 19.70±0.2°, 21.08±0.2°, and 25.64±0.2°.

[Claim 7] The salt of the compound I of any one of claims 2 to 6, characterized in that the XRPD pattern of the crystal form A is substantially as shown in Fig. 1.

[Claim 8] The salt of the compound I of any one of claims 2 to 7, characterized in that the XRPD pattern of the crystal form A is as shown in Fig. 1.

[Claim 9] The salt of the compound I of claim 1, being a crystal form B of the fumarate salt of the compound I, characterized in that an XRPD pattern of the crystal form B comprises diffraction peaks at 2θ of 9.12±0.2°, 16.57±0.2°, 24.78±0.2°, and 25.74±0.2°.

[Claim 10] The salt of the compound I of claim 9, being a crystal form B of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form B further comprises diffraction peaks at 2θ of 15.64±0.2°, 18.05±0.2°, 21.13±0.2°, and 22.08±0.2°.

[Claim 11] The salt of the compound I of claim 9 or 10, being a crystal form B of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form B further comprises diffraction peaks at 2θ of 13.62±0.2°, 15.29±0.2°, 21.81±0.2°, 25.58±0.2°, and 26.91±0.2°.

[Claim 12] The salt of the compound I of any one of claims 9 to 11, being a crystal form B of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form B further comprises diffraction peaks at 2θ of 5.70±0.2°, 11.50±0.2°, 16.26±0.2°, 17.31±0.2°, 19.64±0.2°, 23.87±0.2°, and 27.24±0.2°.

[Claim 13] The salt of the compound I of any one of claims 9 to 12, characterized in that the XRPD pattern of the crystal form B is substantially as shown in Fig. 4.

[Claim 14] The salt of the compound I of any one of claims 9 to 13, characterized in that the XRPD pattern of the crystal form B is as shown in Fig. 4.

[Claim 15] The salt of the compound I of claim 1, being a crystal form C of the fumarate salt of the compound I, characterized in that an XRPD pattern of the crystal form C comprises diffraction peaks at 2θ of 9.13±0.2° and 26.08±0.2°.

[Claim 16] The salt of the compound I of claim 15, being a crystal form C of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form C further comprises diffraction peaks at 2θ of 11.09±0.2°, 17.63±0.2°, 18.08±0.2°, 20.21±0.2°, 22.31±0.2°, and 27.92±0.2°.

[Claim 17] The salt of the compound I of claim 15 or 16, being a crystal form C of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form C further comprises diffraction peaks at 2θ of 10.05±0.2°, 13.27±0.2°, 13.78±0.2°, 14.39±0.2°, and 17.24±0.2°.

[Claim 18] The salt of the compound I of any one of claims 15 to 17, being a crystal form C of the fumarate salt of the compound I, characterized in that the XRPD pattern of the crystal form C further comprises diffraction peaks at 2θ of 8.58±0.2°, 16.84±0.2°, 23.12±0.2°, and 25.13±0.2°.

[Claim 19] The salt of the compound I of any one of claims 15 to 18, characterized in that the XRPD pattern of the crystal form C is substantially as shown in Fig. 6.

[Claim 20] The salt of the compound I of any one of claims 15 to 19, characterized in that the XRPD pattern of the crystal form C is as shown in Fig. 6.

[Claim 21] The salt of the compound I of claim 1, being a crystal form A of the p-toluenesulfonate salt of the compound I, characterized in that an XRPD pattern of the crystal form A comprises diffraction peaks at 2θ of 4.69±0.2° and 13.87±0.2°.

[Claim 22] The salt of the compound I of claim 21, being a crystal form A of the p-toluenesulfonate salt of the compound I, characterized in that the XRPD pattern of the crystal form A further comprises diffraction peaks at 2θ of 16.98±0.2°, 18.23±0.2°, 19.27±0.2°, 19.98±0.2°, 22.08±0.2°, 23.35±0.2°, and 25.78±0.2°.

[Claim 23] The salt of the compound I of claim 21 or 22, being a crystal form A of the p-toluenesulfonate salt of the compound I, characterized in that the XRPD pattern of the crystal


form A further comprises diffraction peaks at 2θ of 8.25±0.2°, 12.23±0.2°, 15.60±0.2°, 17.83±0.2°, 22.49±0.2°, 24.30±0.2°, 25.17±0.2°, and 28.13±0.2°.

[Claim 24] The salt of the compound I of any one of claims 21 to 23, being a crystal form A of the p-toluenesulfonate salt of the compound I, characterized in that the XRPD pattern of the crystal form A further comprises diffraction peaks at 2θ of 10.65±0.2°, 12.77±0.2°, and 20.84±0.2°.

[Claim 25] The salt of the compound I of any one of claims 21 to 24, characterized in that the XRPD pattern of the crystal form A is substantially as shown in Fig. 7.

[Claim 26] The salt of the compound I of any one of claims 21 to 25, characterized in that the XRPD pattern of the crystal form A is as shown in Fig. 7.

[Claim 27] A compound I, being a crystal form I,



I

wherein an XRPD pattern of the crystal form I comprises diffraction peaks at 2θ of 18.00±0.2°, 19.55±0.2°, 22.62±0.2°, and 27.20±0.2°.

[Claim 28] The compound I according to claim 27, wherein the XRPD pattern of the crystal form I further comprises diffraction peaks at 2θ of 5.53±0.2°, 15.95±0.2°, and 18.77±0.2°.

[Claim 29] The compound I according to claim 27 or 28, wherein the XRPD pattern of the crystal form I further comprises diffraction peaks at 2θ of 14.12±0.2°, 14.89±0.2°, 16.89±0.2°, 20.13±0.2°, 20.36±0.2°, 21.71±0.2°, 24.86±0.2°, and 25.67±0.2°.

[Claim 30] The compound I according to any one of claims 27 to 29, wherein the XRPD pattern of the crystal form I further comprises diffraction peaks at 2θ of 11.18±0.2°,

12.33±0.2°, 12.67±0.2°, 12.95±0.2°, 14.46±0.2°, 18.36±0.2°, 20.87±0.2°, 25.13±0.2°, 26.16±0.2°, 26.84±0.2°, 27.80±0.2°, and 28.28±0.2°.

[Claim 31] The compound I of any one of claims 27 to 30, characterized in that the XRPD pattern of the crystal form I is substantially as shown in Fig. 10.

[Claim 32] The compound I of any one of claims 27 to 31, characterized in that the XRPD pattern of the crystal form I is as shown in Fig. 10.

[Claim 33] A pharmaceutical composition, comprising the salt of the compound I of any one of claims 1 to 26 or the compound I in the crystal form I of any one of claims 27 to 32, and one or more pharmaceutically acceptable carriers.

[Claim 34] The pharmaceutical composition of claim 33, wherein the pharmaceutical composition comprises the crystal form A of the fumarate salt of the compound I as defined in any one of claims 2 to 8, or the crystal form B of the fumarate salt of the compound I as defined in any one of claims 9 to 14, or the crystal form C of the fumarate salt of the compound I as defined in any one of claims 15 to 20, or the crystal form A of the p-toluenesulfonate salt of the compound I as defined in any one of claims 21 to 26, or the crystal form I of compound I as defined in any one of claims 27 to 32.

[Claim 35] Use of the salt of the compound I of any one of claims 1 to 26 or the compound I in the crystal form I of any one of claims 27 to 32, or any combination thereof in the preparation of a drug for preventing or treating a disease or condition associated with RET activity.

[Claim 36] The use of claim 35, wherein the salt of the compound I is the crystal form A of the fumarate salt of the compound I as defined in any one of claims 2 to 8, or the crystal form B of the fumarate salt of the compound I as defined in any one of claims 9 to 14, or the crystal form C of the fumarate salt of the compound I as defined in any one of claims 15 to 20, or the crystal form A of the p-toluenesulfonate salt of the compound I as defined in any one of claims 21 to 26.

[Claim 37] The use of claim 35 or 36, wherein the disease or condition associated with RET activity is irritable bowel syndrome, or cancer or tumor.

[Claim 38] The use of claim 37, wherein the cancer or tumor is lung cancer, breast cancer, head and neck cancer, rectal cancer, liver cancer, lymphoma, thyroid cancer, colon cancer, multiple myeloma, melanoma, glioma, brain tumor, or sarcoma.

[Claim 39] The use of claim 38, wherein the lung cancer is non-small cell lung cancer; the thyroid cancer is medullary thyroid cancer or papillary thyroid cancer.